Lymphocytes in Psychiatric Disorders

Overview

About this study

The purpose of this research is to understand if a blood test can be developed to aid in diagnosing neuropsychiatric disorders.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Demographic characteristics: ≥ 18 and < 70 years of age.
  • Health status: any schizophrenia spectrum disorder as defined by the DSM5 for case group; psychiatric control group can have any DSM-5 defined Bipolar, Depressive, or Anxiety Disorders; healthy controls have no psychiatric illness as defined by DSM-5.
  • Ability to understand risks of blood draw.

Exclusion Criteria

All candidates meeting any of the exclusion criteria will be excluded from study participation:

  • Demographic characteristics: < 18 or ≥ 70 years of age.
  • Use of rituximab or other similar medications that cause lymphocyte cell death in the past 6 months.
  • Inability or unwillingness of individual to give written informed consent.
  • Fever, chills, or other objective evidence of ongoing infection at a time of the blood draw.

Special Subpopulations

  • Individuals with legal guardians can participate in the study, as long as both participant and guardian both agree to participation. Guardian will sign the consent form.
  • Currently involuntary hospitalized patients will not be recruited and will be excluded from this study.
  • We anticipate adequate recruitment of racial and other minorities, based on past recruitment experience with similar patient population (e.g. 29% of participants in IRB#21011143 were African American).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/23/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matej Markota, M.D.

Contact us for the latest status

Contact information:

Sarah Purdy

(507) 266-3303

Purdy.Sarah@mayo.edu

More information

Publications

Publications are currently not available